Proposed Data Collection Submitted for Public Comment and Recommendations, 14000-14002 [2017-05265]

Download as PDF 14000 Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices The Commission will use the information collected to meet its statutory requirement under the WARN Act to accept licensees’ election filings and to establish an effective CMAS that will provide the public with effective mobile alerts in a manner that imposes minimal regulatory burdens on affected entities. to Mr. Robert E. Feldman, Executive Secretary of the Corporation, at 202– 898–7043. Dated: March 13, 2017. Federal Deposit Insurance Corporation. Robert E. Feldman, Executive Secretary. [FR Doc. 2017–05352 Filed 3–14–17; 11:15 am] BILLING CODE P Federal Communications Commission. Marlene H. Dortch, Secretary, Office of the Secretary. FEDERAL ELECTION COMMISSION [FR Doc. 2017–05184 Filed 3–15–17; 8:45 am] Sunshine Act Meeting BILLING CODE 6712–01–P Federal Election Commission Tuesday, March 21, 2017 at 10:00 a.m. and its continuation at the conclusion of the open meeting on March 23, 2017. PLACE: 999 E Street, NW., Washington, DC. STATUS: This meeting will be closed to the public. ITEMS TO BE DISCUSSED: Compliance matters pursuant to 52 U.S.C. 30109. Matters relating to internal personnel decisions, or internal rules and practices. Information the premature disclosure of which would be likely to have a considerable adverse effect on the implementation of a proposed Commission action. * * * * * PERSON TO CONTACT FOR INFORMATION: Judith Ingram, Press Officer, Telephone: (202) 694–1220. AGENCY: DATE AND TIME: FEDERAL DEPOSIT INSURANCE CORPORATION mstockstill on DSK3G9T082PROD with NOTICES Sunshine Act Meeting Pursuant to the provisions of the ‘‘Government in the Sunshine Act’’ (5 U.S.C. 552b), notice is hereby given that the Federal Deposit Insurance Corporation’s Board of Directors will meet in open session at 10:00 a.m. on Tuesday, March 21, 2017, to consider the following matters: Summary Agenda: No substantive discussion of the following items is anticipated. These matters will be resolved with a single vote unless a member of the Board of Directors requests that an item be moved to the discussion agenda. Disposition of minutes of previous Board of Directors’ Meetings. Summary reports, status reports, reports of actions taken pursuant to authority delegated by the Board of Directors, and reports of the Office of Inspector General. Discussion Agenda: Update of Projected Deposit Insurance Fund Losses, Income, and Reserve Ratios for the Restoration Plan. The meeting will be held in the Board Room located on the sixth floor of the FDIC Building located at 550 17th Street NW., Washington, DC. This Board meeting will be Webcast live via the Internet and subsequently made available on-demand approximately one week after the event. Visit https://fdic.windrosemedia.com to view the event. If you need any technical assistance, please visit our Video Help page at: https:// www.fdic.gov/video.html. The FDIC will provide attendees with auxiliary aids (e.g., sign language interpretation) required for this meeting. Those attendees needing such assistance should call 703–562–2404 (Voice) or 703–649–4354 (Video Phone) to make necessary arrangements. Requests for further information concerning the meeting may be directed VerDate Sep<11>2014 17:12 Mar 15, 2017 Jkt 241001 Dayna C. Brown, Secretary and Clerk of the Commission. [FR Doc. 2017–05397 Filed 3–14–17; 4:15 pm] available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 10, 2017. A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001: 1. Bern Bancshares, Inc., Bern, Kansas; to acquire up to 6.36 percent of the voting shares of UBT Bancshares, Inc., Marysville, Kansas, and thereby indirectly acquire United Bank & Trust, Marysville, Kansas. Board of Governors of the Federal Reserve System, March 13, 2017. Yao-Chin Chao, Assistant Secretary of the Board. [FR Doc. 2017–05241 Filed 3–15–17; 8:45 am] BILLING CODE 6210–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention BILLING CODE 6715–01–P [60Day–17–17SG; Docket No. CDC–2017– 0016] FEDERAL RESERVE SYSTEM Proposed Data Collection Submitted for Public Comment and Recommendations Formations of, Acquisitions by, and Mergers of Bank Holding Companies The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Centers for Disease Control and Prevention (CDC), as part of its continuing efforts to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995. This notice invites comment on the proposed information collection project titled ‘‘Anthropometric Information on Law Enforcement Officers.’’ The purpose of SUMMARY: E:\FR\FM\16MRN1.SGM 16MRN1 mstockstill on DSK3G9T082PROD with NOTICES Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices this three-year data collection project is to assemble a database of body dimensions of 1,000 law enforcement officers to improve the design of police cruiser cabins and personal protective equipment (PPE). DATES: Written comments must be received on or before May 15, 2017. ADDRESSES: You may submit comments, identified by Docket No. CDC–2017– 0016 by any of the following methods: • Federal eRulemaking Portal: Regulations.gov. Follow the instructions for submitting comments. • Mail: Leroy A. Richardson, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS– D74, Atlanta, Georgia 30329. Instructions: All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to Regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to Regulations.gov. Please note: All public comment should be submitted through the Federal eRulemaking portal (Regulations.gov) or by U.S. mail to the address listed above. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact the Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS–D74, Atlanta, Georgia 30329; phone: 404–639–7570; Email: omb@cdc.gov. SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance VerDate Sep<11>2014 17:12 Mar 15, 2017 Jkt 241001 of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information. Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information, to search data sources, to complete and review the collection of information; and to transmit or otherwise disclose the information. Proposed Project Anthropometric Information on Law Enforcement Officers—New—National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC). Background and Brief Description The mission of the National Institute for Occupational Safety and Health (NIOSH) is to promote safety and health at work for all people through research and prevention. The National Bureau of Standards (NBS) released its manually measured anthropometric data of law enforcement officer (LEOs) in 1975. The data have largely become outdated due to demographic changes (e.g., gender and race/ethnicity) that have occurred in the past 41 years. NIOSH has initiated a national study on LEO anthropometry, using both traditional and three-dimensional (3D) scanning technologies to advance the safety and health of approximately 817,000 U.S. LEOs. Traditional anthropometry will ensure easy comparison of data between this and previous studies, whereas 3D scan information (body contours and spatial relations between body parts) will be used for advanced PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 14001 anthropometric analysis, computer simulation, and modeling. Study results will be used to enhance design and standards for LEO vehicle configuration and personal protective equipment (PPE), such as cabins, seats, body restraints, vehicle access, and body armor. Law enforcement officer anthropometry has an important role in the design of ergonomically efficient LEO cruisers and personal protective systems. The improved vehicle configurations will help enhance safe operation (due to improved driver visibility and control operation) and increase post-crash survivability (due to enhanced seats and restraint system configurations). Body armor, helmet, gloves, and boots are important elements of an integrated LEO personal protective system, especially for handling violent acts. Poor equipment fit may compromise protective capabilities of PPE and may result in LEOs not wearing the PPE because of discomfort. By establishing an anthropometric database for LEOs, the designers and manufacturers of these types of equipment will be able to produce more effective products and reduce the problems associated with sizing and stocking these items. Data collection will occur in four U.S. geographic areas using traditional anthropometric techniques for whole body measurements, 3D scanning techniques for head, foot, and whole body measurements, and a twodimensional(2D) scanning techniques for hand measurements. An anthropometer, a beam caliper (rearranged pieces of the anthropometer), tape measures, and an electronic scale will be used to collect the traditional anthropometry data in the study. A hand scanner, head scanner, foot scanner, and whole body scanner, housed in a mobile trailer, are used for 2D and 3D body shape measurements. The study population will be current law enforcement officers employed by police departments, sheriff’s departments, or similar governmental organizations throughout the continental United States. One thousand LEO volunteers will participate in the study over three years. Informed consent and the data collection are expected to take no longer than 65 minutes (total) to complete. The total estimated annualized burden hours are 385. There are no costs to the respondents other than their time. Estimated Annualized Burden Hours E:\FR\FM\16MRN1.SGM 16MRN1 14002 Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices Type of respondents Law Law Law Law Enforcement Enforcement Enforcement Enforcement Officers Officers Officers Officers Number of respondents Form name ................ ................ ................ ................ Average burden per response (in hrs) Number of responses per respondent Total burden (in hrs) 333 333 333 333 1 1 1 1 1/60 3/60 5/60 30/60 6 17 28 167 Law Enforcement Officers ................ Pre-Enrollment Confirmation Email .. Biographical Information .................. Consent form .................................... Traditional anthropometric measurements. 2D and 3D scans ............................. 333 1 30/60 167 Total ........................................... ........................................................... ........................ ........................ ........................ 385 Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. Dated: March 13, 2017. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2017–05265 Filed 3–15–17; 8:45 am] [FR Doc. 2017–05247 Filed 3–15–17; 8:45 am] BILLING CODE 4163–18–P BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Food and Drug Administration [Docket No. FDA–N–2016–4198] [Docket No. FDA–2016–P–1676] Public Meeting on Patient-Focused Drug Development for Sarcopenia; Request for Comments; Correction Determination that CYANOCOBALAMIN INJECTION, 1 Milligram per Milliliter in a 10 Milliliter Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness AGENCY: Food and Drug Administration, HHS. ACTION: AGENCY: Notice; correction. The Food and Drug Administration is correcting a notice entitled ‘‘Public Meeting on PatientFocused Drug Development for Sarcopenia’’ that appeared in the Federal Register of December 14, 2016 (81 FR 90361). The document announced a public meeting and an opportunity for public comment on Patient-Focused Drug Development for Sarcopenia. The location of the meeting has changed and this document provides the updated meeting location. FOR FURTHER INFORMATION CONTACT: Meghana Chalasani, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 1146, Silver Spring, MD 20993–0002, 240– 402–6525, FAX: 301–847–8443, Meghana.Chalasani@fda.hhs.gov. In the Federal Register of Wednesday, December 14, 2016, in FR Doc. 2016– 29998, the following correction is made: 1. On page 90361, in the second column, in the first sentence of the ADDRESSES section, ‘‘FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room, (Rm. 1503), Silver Spring, MD 20993–0002.’’ is corrected to read ‘‘Tommy Douglas Conference Center, mstockstill on DSK3G9T082PROD with NOTICES 17:12 Mar 15, 2017 Food and Drug Administration, HHS. SUMMARY: VerDate Sep<11>2014 10000 New Hampshire Ave., Silver Spring, MD 20903.’’ Jkt 241001 ACTION: Notice. The Food and Drug Administration (FDA or Agency) has determined that CYANOCOBALAMIN INJECTION, 1 milligram per milliliter in a 10 milliliter vial, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements. FOR FURTHER INFORMATION CONTACT: Elizabeth Trentacost, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6219, Silver Spring, MD 20993–0002, 240– 402–7736. SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products under an ANDA procedure. ANDA applicants SUMMARY: PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength, dosage form, and route of administration as the ‘‘listed drug,’’ which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ‘‘Approved Drug Products With Therapeutic Equivalence Evaluations,’’ which is known generally as the ‘‘Orange Book.’’ Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug’s NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162). A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (21 CFR 314.161). FDA may not approve an ANDA that does not refer to a listed drug. CYANOCOBALAMIN INJECTION, 1 milligram per milliliter in a 10 milliliter vial, is the subject of ANDA 080557, held by Fresenius Kabi USA (Fresenius), and initially approved on June 20, 1973. CYANOCOBALAMIN INJECTION is indicated for vitamin B12 deficiencies due to malabsorption that may be associated with the following conditions: Addisonian (pernicious) anemia; gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, and total or partial gastrectomy; fish tapeworm E:\FR\FM\16MRN1.SGM 16MRN1

Agencies

[Federal Register Volume 82, Number 50 (Thursday, March 16, 2017)]
[Notices]
[Pages 14000-14002]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05265]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-17-17SG; Docket No. CDC-2017-0016]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing efforts to reduce public burden and maximize the 
utility of government information, invites the general public and other 
Federal agencies to take this opportunity to comment on proposed and/or 
continuing information collections, as required by the Paperwork 
Reduction Act of 1995. This notice invites comment on the proposed 
information collection project titled ``Anthropometric Information on 
Law Enforcement Officers.'' The purpose of

[[Page 14001]]

this three-year data collection project is to assemble a database of 
body dimensions of 1,000 law enforcement officers to improve the design 
of police cruiser cabins and personal protective equipment (PPE).

DATES: Written comments must be received on or before May 15, 2017.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2017-
0016 by any of the following methods:
     Federal eRulemaking Portal: Regulations.gov. Follow the 
instructions for submitting comments.
     Mail: Leroy A. Richardson, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE., MS-D74, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. All relevant comments received will be posted 
without change to Regulations.gov, including any personal information 
provided. For access to the docket to read background documents or 
comments received, go to Regulations.gov.
    Please note: All public comment should be submitted through the 
Federal eRulemaking portal (Regulations.gov) or by U.S. mail to the 
address listed above.

FOR FURTHER INFORMATION CONTACT: To request more information on the 
proposed project or to obtain a copy of the information collection plan 
and instruments, contact the Information Collection Review Office, 
Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS-
D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: omb@cdc.gov.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
Federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; (d) ways to 
minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology; and (e) estimates of capital or start-
up costs and costs of operation, maintenance, and purchase of services 
to provide information. Burden means the total time, effort, or 
financial resources expended by persons to generate, maintain, retain, 
disclose or provide information to or for a Federal agency. This 
includes the time needed to review instructions; to develop, acquire, 
install and utilize technology and systems for the purpose of 
collecting, validating and verifying information, processing and 
maintaining information, and disclosing and providing information; to 
train personnel and to be able to respond to a collection of 
information, to search data sources, to complete and review the 
collection of information; and to transmit or otherwise disclose the 
information.

Proposed Project

    Anthropometric Information on Law Enforcement Officers--New--
National Institute for Occupational Safety and Health (NIOSH), Centers 
for Disease Control and Prevention (CDC).

Background and Brief Description

    The mission of the National Institute for Occupational Safety and 
Health (NIOSH) is to promote safety and health at work for all people 
through research and prevention. The National Bureau of Standards (NBS) 
released its manually measured anthropometric data of law enforcement 
officer (LEOs) in 1975. The data have largely become outdated due to 
demographic changes (e.g., gender and race/ethnicity) that have 
occurred in the past 41 years. NIOSH has initiated a national study on 
LEO anthropometry, using both traditional and three-dimensional (3D) 
scanning technologies to advance the safety and health of approximately 
817,000 U.S. LEOs.
    Traditional anthropometry will ensure easy comparison of data 
between this and previous studies, whereas 3D scan information (body 
contours and spatial relations between body parts) will be used for 
advanced anthropometric analysis, computer simulation, and modeling. 
Study results will be used to enhance design and standards for LEO 
vehicle configuration and personal protective equipment (PPE), such as 
cabins, seats, body restraints, vehicle access, and body armor. Law 
enforcement officer anthropometry has an important role in the design 
of ergonomically efficient LEO cruisers and personal protective 
systems. The improved vehicle configurations will help enhance safe 
operation (due to improved driver visibility and control operation) and 
increase post-crash survivability (due to enhanced seats and restraint 
system configurations). Body armor, helmet, gloves, and boots are 
important elements of an integrated LEO personal protective system, 
especially for handling violent acts. Poor equipment fit may compromise 
protective capabilities of PPE and may result in LEOs not wearing the 
PPE because of discomfort. By establishing an anthropometric database 
for LEOs, the designers and manufacturers of these types of equipment 
will be able to produce more effective products and reduce the problems 
associated with sizing and stocking these items.
    Data collection will occur in four U.S. geographic areas using 
traditional anthropometric techniques for whole body measurements, 3D 
scanning techniques for head, foot, and whole body measurements, and a 
two-dimensional(2D) scanning techniques for hand measurements. An 
anthropometer, a beam caliper (rearranged pieces of the anthropometer), 
tape measures, and an electronic scale will be used to collect the 
traditional anthropometry data in the study. A hand scanner, head 
scanner, foot scanner, and whole body scanner, housed in a mobile 
trailer, are used for 2D and 3D body shape measurements.
    The study population will be current law enforcement officers 
employed by police departments, sheriff's departments, or similar 
governmental organizations throughout the continental United States. 
One thousand LEO volunteers will participate in the study over three 
years. Informed consent and the data collection are expected to take no 
longer than 65 minutes (total) to complete. The total estimated 
annualized burden hours are 385.
    There are no costs to the respondents other than their time.

Estimated Annualized Burden Hours

[[Page 14002]]



----------------------------------------------------------------------------------------------------------------
                                                                                      Average
                                                     Number of       Number of      burden per     Total burden
      Type of respondents           Form name       respondents    responses per   response  (in     (in hrs)
                                                                    respondent         hrs)
----------------------------------------------------------------------------------------------------------------
Law Enforcement Officers......  Pre-Enrollment               333               1            1/60               6
                                 Confirmation
                                 Email.
Law Enforcement Officers......  Biographical                 333               1            3/60              17
                                 Information.
Law Enforcement Officers......  Consent form....             333               1            5/60              28
Law Enforcement Officers......  Traditional                  333               1           30/60             167
                                 anthropometric
                                 measurements.
Law Enforcement Officers......  2D and 3D scans.             333               1           30/60             167
                                                                                                 ---------------
    Total.....................  ................  ..............  ..............  ..............             385
----------------------------------------------------------------------------------------------------------------


Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-05265 Filed 3-15-17; 8:45 am]
 BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.